Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Tulek, E. Kiyan, H. Toy, A. Kiyici, C. Narin, M. Suerdem (Konya, Turkey). Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2010; 36: Suppl. 54, 4222

Member's Comments

No comment yet.

Related content which might interest you: Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Antioxidant and anti-inflammation effect of GHK-Cu in bleomycin-induced pulmonary fibrosis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis:  mechanistic insights and prognostic markers Year: 2018 Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Time course of bleomycin-induced pulmonary fibrosis and the antifibrotic effect of losartan Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease Year: 2007 The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2006; 28: Suppl. 50, 827s Year: 2006 Therapeutic effect of combination of salvia and ligustrazine on bleomycin-induced pulmonary fibrosis Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Effects of drotrecogin-alpha on the bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Inhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 The effect of interferon-γ on bleomycin-induced alveolitis and pulmonary fibrosis in rats Source: Eur Respir J 2005; 26: Suppl. 49, 81s Year: 2005 Effects of aerosolized earthworm fibrinolytic enzyme on bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2006; 28: Suppl. 50, 766s Year: 2006 Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias Year: 2018 Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013